Clinical Trials Browser

Phase 1 × Liposarcoma, Myxoid × Clear all

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Recruiting

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT06414434 2026-04-30

BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

Phase 1 Active not recruiting

24 enrolled

Sarcoma

Liposarcoma, Liposarcoma, Myxoid

NCT06083883 2026-04-16

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Phase 1 Recruiting

44 enrolled

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06644755 2025-07-24

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Phase 1 Recruiting

150 enrolled

GenitourinarySarcoma

Urinary Bladder Neoplasms, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06748872 2024-12-27

EPITOME-1015-I

Phase 1 Not yet recruiting

55 enrolled

GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04526509 2024-11-26

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Phase 1 Terminated

12 enrolled 12 charts

Sarcoma

Neoplasms, Liposarcoma, Myxoid

NCT05943990 2024-11-13

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 1 Terminated

5 enrolled 16 charts

Sarcoma

Neoplasms, Liposarcoma, Myxoid

NCT06048705 2024-11-13

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase 1 Terminated

7 enrolled 19 charts

SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Liposarcoma, Myxoid

NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Phase 1 Terminated

27 enrolled

Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1 Unknown

50 enrolled

Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT03450122 2023-10-16

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

Phase 1 Completed

15 enrolled

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT03399448 2023-06-22

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Phase 1 Terminated

3 enrolled

DermatologicPlasma cellSarcoma

Melanoma, Multiple Myeloma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT02059850 2016-02-03

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 1 Withdrawn

Sarcoma

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Clinical Trials

MAGE-A4ᶜ¹º³²T for Multi-Tumor

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

EPITOME-1015-I

Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma